PI3K Mutations Detected in Liquid Biopsy in Metastatic Breast Cancer Patients

PI3K Mutations Detected in Liquid Biopsy Are Associated With Reduced Sensitivity to CDK4/6 Inhibitors in Metastatic Breast Cancer Patients.
TAKE-HOME MESSAGE
The authors of this retrospective analysis utilized plasma samples from patients with metastatic breast cancer treated with CDK4/6 inhibitors and hormonal therapy to evaluate the predictive nature of baseline PIK3CA mutations in circulating free DNA (cfDNA). Baseline PIK3CA mutation detected via cfDNA was associated with both higher Ki67 expression and shorter progression-free survival.

The PIK3CA mutational profile detected using cfDNA analysis could serve as a biomarker for survival with exposure to CDK4/6 inhibitors. While promising, these data will need further validation in a larger sample to further clarify this predictive relationship.

CONCLUSION
The findings of this pilot study suggest that the presence of a PI3K mutation in liquid biopsy correlates with a worse PFS in patients with advanced breast cancer(ABC) receiving CDK4/6i, and that liquid biopsy is a useful tool to suggests a better tailored pharmacological intervention.

https://www.practiceupdate.com/content/pi3k-mutations-detected-in-liquid-biopsy-are-associated-with-reduced-sensitivity-to-cdk46-inhibitors-in-metastatic-breast-cancer-patients/108383/15/13/1

IMO, the Paxalisib data results from the ALLIANCE trial next year, by identifying the patients with the PI3K mutation to be treated (ie, a better tailored pharmacological intervention), should see a better outcome for those treated patients.

Regards.